الفهرس 
Type 2 diabetes mellitusOnly 14 pages are availabe for public view
 |  | from | 174 |  |  |
| | | from | 174 | | |
Abstract
This clinical study was designed to investigate the role of niclosamide and fexofenadine in reducing albuminuria in patients with diabetic kidney disease (DKD). Patients and methods: from January 2020 to April 2022, out of 201 patients screened for eligibility, 91 patients were randomly enrolled into three groups, the control group (n=31): patients received ramipril 10 mg tab only for six months, the niclosamide group (n=30): patients received ramipril 10 mg tab plus niclosamide 1 gm tab once daily; and the fexofenadine group (n=30): patients received ramipril 10 mg tab plus fexofenadine 60 mg daily. Blood and urine samples were obtained at baseline and at the end of the study for measuring urinary albumin to creatinine ratio (UACR), serum creatinine, estimated glomerular filtration rate (eGFR), matrix metalloproteinase-7 (MMP-7), monocyte chemoattractant protein-1 (MCP-1), 8-hydroxy-2’ -deoxyguanosine (8-OHdG), and podocalyxin (PCX).